Disclosures
J. Leung, Novartis, Fresenius Kabi, Eli Lilly, AbbVie; C. Owen, none; D. Liew, none; R. Buchanan, none.
Jessica Leung, MBBS, FRACP, Claire E. Owen, MBBS, PhD, FRACP, David Liew, MBBS, FRACP, & Russell Buchanan, MBBS, MD, FRACP |
J. Leung, Novartis, Fresenius Kabi, Eli Lilly, AbbVie; C. Owen, none; D. Liew, none; R. Buchanan, none.
Sleep disturbance is an important medical problem, requiring intervention, not simply to reduce latency to its onset, but to ensure achievement of the depth of sleep that has been documented to restore homeostasis and prevent the falls that are responsible for so much morbidity and mortality.1 Sleep disturbance is present in 50% of people over…
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously
Why screening for depressive symptoms in patients with arthritis is needed
Chronic insomnia is a common complaint for patients with rheumatic diseases and conditions. In fact, sleep disturbances are among the most common symptoms of both fibromyalgia and rheumatoid arthritis (RA), with more than 50% of chronic pain patients reporting sleep disturbances. Pain combined with insomnia can lead to a vicious cycle, says Ruth Gentry, PhD,…